Latest Liquidity News

MPower Group Limited has announced a binding agreement to sell its main renewable energy assets for approximately $19 million, reporting a net loss of $4.1 million for FY2025 largely due to discontinued operations.

Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.64 million for the half-year ended June 2025, yet its net loss widened by 12.2% to $3.09 million, reflecting higher marketing and restructuring expenses following recent acquisitions.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Pengana Private Equity Trust reported a robust FY25 with a 7.6% NAV increase and a strong net profit of $50 million, underpinned by a diversified global private equity portfolio and a strategic buyback program.

Vmoto Limited reported a 10.8% revenue decline to $20.8 million in H1 2025 but reduced its net loss slightly to $3 million, buoyed by resilient international sales and a strategic partnership with Uber to electrify delivery fleets across Europe.

Steamships Trading Company Limited reported a modest 1.7% dip in half-year profit despite a 6.7% rise in revenue, driven by strong divisional performances and significant property gains. The company’s increased capital investment and cautious outlook highlight ongoing challenges and opportunities in Papua New Guinea’s economic landscape.

Saferoads Holdings Limited reported a net profit of $4.35 million for FY2025, driven largely by a $5.27 million gain from the sale of its Road Safety Rental business. Continuing operations showed a modest loss amid a 14% revenue decline.

Victor Group Holdings has sharply reduced its FY25 loss to $275,449 from $3.53 million the prior year, while expanding its fintech presence through strategic stakes in LIT Technology and iRich Finance.

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.